Company Profile

Sourcing Inquiry Logo Aurelia Bioscience

Aurelia Bioscience

United Kingdom
Human Medicines
Service category
Pre-clinical development and testing, pre-clinical CRO
Content posted and uploaded by users. Want to add your company?
Your company? Get access to this profile.

Key services


Our Services


  • High Throughput Screening

  • Cell Culture Services

  • Phenotypic Screening

  • Biochemical Screening

  • Label-Free Screening

  • FLIPR Screening

  • FMAT Screening

  • Cell-Based Screening


Fee for Service


A comprehensive service to drug discovery clients including……

  • assay development (cell-based or biochemical)
  • reagent testing and scale-up (recombinant cells or protein)
  • proof of concept with validation (activity of known compounds in the chosen assay)
  • high throughput screening (many compounds, one assay)
  • compound profiling (few compound, many assays)


Our “fee for service” model is simple; we charge a set fee for our assay development services and a subsequent fee per well for each compound screened.


We design, develop and build assays to suit your needs following consultation with you. We either source reagents from suppliers, manufacture them according to the needs of your project, or use the reagents provided by you. We validate your assay using any pharmacological tools available in the most appropriate plate format selected for screening purposes. We charge clients a set fee for assay development work. Costs are dependent on assay complexity and project timelines.


The second stage of the project is screening compounds in an assay for pharmacological charaterisation. We charge clients a fee per well for each well screened. Costs reflect the assay and plate format. If we can miniaturise your assay into 384 well or 1536 well plates we will pass on savings to our clients through a reduced fees per well. The screening of large numbers of compounds will also introduce savings in terms of the fee per well as we can pass on bulk discounts on externally sourced reagents to our clients.



In addition we also provide a consultation service on the development of assay cascades designed to increase the physiological relevance of your data whilst reducing the number of non-specific compounds in the output by developing the most appropriate assays for the project.



Instrument and Reagent Development


Acting as an intermediary between instrument manufacturers and reagent manufacturers and prospective clients, we can provide an expert lab-based environment for the validation of new technologies. We can bridge the gap between clients and instrument manufacturers to validate new technologies and develop novel applications for existing technologies using our “real world” screening expertise.


For over a decade we have collaborated with many instrument manufacturers to develop and apply new and novel technology to drug discovery. Examples include; Molecular Devices FLIPR, FLIPRTetra and FLIPRTetra Jellyfish, Corning Epic label-free, Amersham IN-Cell high content screening, DiscoveRx beta –arrestin based screening, Applied Biosystems FMAT for bead-based FLISA and cell-based competition assays and Labcyte Echo 555 acoustic dispensing and Microsonic system acoustic mixing.


Data Generated when Validating an Echo 555 from Labcyte Inc. Left panel showns a Labcyte 555 ultrasonic dispenser used to dispense compounds in triplicate into plates and screened within a 384 well FMAT binding assay. Right panel shows the correlation between each compound, each of the three values per compound are plotted on the X, Y and Z axis - data plotted using the Spotfire application.


Data Generated Validating the Hendrix Mixer from Microsonic Systems Inc. A fragment-based series as screened at high concentration within a kinase assay. Predicted hits did not give dose response curves consistent with activity (panel A). Compounds were subjected to mixing using the Hendix mixer (shown inset) and the assay repeated. Compounds were then active at high concentration (panel B) suggesting that they were insoluble under normal conditions and the ultrasonic mixing re-solubilised the compounds. Using all of the technologies above we have successfully performed phenotypic screens for endogenously expressed targets in primary cells obtained from humans without the intervention of molecular biology to introduce reporters to these systems.


We can provide services to clients who require:


An intermediary company to work between the instrument manufacturer and the client to validate the technology for the client application and/or biology. 


Manufacturers wishing to identify and engage with a group of our scientists who can push their technology to the limit and identify the “killer application”.


Instrument and reagent manufactures from overseas wishing to establish a technology support base and training support in the UK.


Drug Discovery Project


The members of Aurelia Bioscience have been involved in the design and development of many drug discovery projects incorporating complex biology and implementing a suite of assays designed to identify “active” compounds and improve their biological properties. These properties include potency, selectivity and cell penetration. This work has involved consultation with project and target biologists to determine the most appropriate assay for the initial screen and any subsequent assays that many be required to remove compounds with unwanted off target effects, cross-over to other target family members as well as false positive compounds i.e. those that are active as a consequence of interacting with the reporting technology rather than the target directly.


A “drug discovery project” is therefore distinct from “fee for service” as it represents a body of work, usually time constrained, that incorporates a number of assays, a number of targets and a number of approaches, all designed to result in a rapid, iterative, compound-based design-make-test cycle for the medicinal chemists of our clients. The project is designed initially to test a large number of compounds and identify those with desirable properties, followed by further assays designed to help build potency, selectivity and specificity and remove unwanted properties of the lead molecules.


We can suggest a number of approaches to screening your target based on the type of target, the screening approach, the format and the projected timelines for completion. We have mapped out a generic screening cascade here that gives some indication of the type of approaches we have adopted when putting together a project.


We are very experienced in the respiratory and inflammatory biology research area and we have designed assays for other research areas including oncology and CNS-pain.


Special projects

You might be also interested in

Sourcing this company's services?

Send inquiry anonymously »

Or add this Company to
Sourcing cart